Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST. The presentation is virtual and will be webcast.
The webcast will be available for 90 days via the conference link or Aprea's Investors "News & Events" page. Investors may request 1:1 meetings through their Oppenheimer representative.
Details
News Market Reaction – APRE
On Feb 17, the day this news came out, APRE closed 1.54% below the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Conference dates
- February 25–26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Presentation time
- February 26, 2026, 8:40 am EST
- Scheduled corporate update webcast
- Webcast availability
- 90 days
- Replay available on company website and conference link
Historical Context
-
Expanded global DDR oncology patent estate with protection potentially to 2045.
-
Appointed experienced Chief Medical Advisor after early proof-of-concept for APR-1051.
-
Reported early proof-of-concept and unconfirmed partial response in ACESOT-1051 trial.
-
Announced $5.6M private placement with new shares and warrants at $0.89 per unit.
-
CEO summarized 2025 progress, clinical plans for 2026, and cash runway into Q1 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually.
Presentation Details
| Date/ time: | February 26, 2026 8:40 am EST |
| Location: | Virtual |
| Webcast link: | click here |
The webcast will be available for 90 days at the link above or on the Investors page of the Aprea corporate website, under “News & Events.”
Investors who would like to arrange a 1on1 meeting with Aprea management during the conference should contact their Oppenheimer representative.
About Aprea
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma.
The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.